Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi, W; Jiang, T; Nuciforo, P; Hatzis, C; Holmes, E; Harbeck, N; Sotiriou, C; Peña, L; Loi, S; Rosa, D; Chia, S; Wardley, Andrew M; Ueno, T; Rossari, J; Eidtmann, H; Armour, A; Piccart-Gebhart, M; Rimm, D; Baselga, J; Pusztai, L

Affiliation

Yale University, Yale Cancer Center, New Haven CT;Yale University, Yale Cancer Center, New Haven CT

Issue Date

2016-09-29

Metadata

Show full item record

Abstract

We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival.

Citation

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. 2016, Ann Oncol

Journal

Annals of Oncology

URI

http://hdl.handle.net/10541/619976

DOI

10.1093/annonc/mdw434

PubMed ID

27687302

Type

Article

Language

ISSN

1569-8041

Collections

All Christie Publications